SynthesisRenal failure2025
The mechanisms of kidney-lung interactions in chronic kidney disease-associated pulmonary diseases: A two-sample Mendelian randomization study.
Synthesis in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liuweidihuang Pill Attenuates Early Bleomycin-Induced Pulmonary Fibrosis in Mice and Is Associated with Gut Microbiome.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to investigate the relationship between chronic kidney disease and pulmonary diseases, and explore the mechanisms of kidney-lung interactions.
methodsTwo-sample Mendelian randomization (MR) was performed to explore the causal effect of chronic kidney disease (CKD) on pulmonary diseases, and two-step MR was performed to explore the mechanisms of lung-kidney interactions in chronic kidney disease-associated pulmonary diseases. The inverse variance weighted (IVW) meta-analysis was used as the main method for obtaining the MR estimate, and complementary analysis were performed using the weighted median method, maximum-likelihood, MR-RAPS.
resultsIVW analysis showed that genetically predicted CKD was positively associated with the increased risks of asthma (OR:1.005, 95%CI:1.001, 1.009), pneumonia (OR:1.066, 95%CI: 1.009, 1.127), adult respiratory distress syndrome (ARDS) (OR:2.110, 95%CI: 1.053, 4.231), and chronic obstructive pulmonary disease (COPD) (OR, 1.004; 95%CI:1.000, 1.008). Mediation analysis revealed that interleukin-1β mediated CKD's effect on pneumonia risk, tumor necrosis-α mediated its effects on both asthma and COPD, and parathyroid hormone (PTH) mediated its effects on pneumonia and ARDS, with mediated effects size ranging from 3.53% to 27.15%.
conclusionsPredicted CKD was positively associated with the increased risk of asthma, pneumonia, ARDS, and COPD. Furthermore, interleukin-1β and tumor necrosis-α, 25-hydroxyvitamin D and PTH mediated the kidney-lung interactions in CKD-associated pulmonary diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.